By: Kanto
Kai Okanta
Kenya has advanced plans to
develop a proposed Biopharma Life Sciences Park at Konza Technopolis following
the signing of a feasibility study grant agreement involving Apifa Biotech and
global professional services firm JLL.
The agreement brings
together key partners supporting the assessment and development of the proposed
facility, which is expected to strengthen pharmaceutical manufacturing and
expand opportunities within Kenya's life sciences industry.
The Technopolis Development
Authority, formerly the Konza Technopolis Development Authority, and Swedfund
International have formalised their support for the feasibility study, while
Apifa Biotech Limited is advancing the project as its proponent.
The JLL–IQVIA consortium
will provide the technical expertise required to assess the project's potential
and establish the groundwork for the proposed development.
According to the Technopolis
Development Authority, the collaboration reflects the importance of
partnerships in advancing projects built around a shared vision.
The proposed Biopharma Life
Sciences Park forms part of efforts to strengthen Kenya's pharmaceutical
manufacturing capabilities and create opportunities for growth in the life
sciences sector.
The feasibility study is
expected to provide an assessment of the project's potential, helping establish
the basis for its further development at Konza Technopolis.
